Outcomes of HIDAC 18 g Versus IDAC 9 g in Consolidation Therapy of Acute Myeloid Leukemia: A Retrospective Study.

ABSTRACT:

Background

Cytarabine based therapy has been the standard consolidation regimen for AML (acute myeloid leukemia) for decades. However, the optimal dose, regimen and schedule is not known. HIDAC (high dose cytarabine at 18 g/m²) has been the conventional standard, however, recent studies have shown that intermediate doses of cytarabine (IDAC) have equal efficacy and lesser toxicities.

Methods

We retrospectively analysed 75 AML patients who entered consolidation out of 167 patients who underwent induction therapy between 2014 and 2018. HIDAC (at 18 g/m²) was given to 39 patients and 36 patients received IDAC at 9 g/m².

Results

Median age was 28 years (range 2-60). Male: female ratio was 1.02. More courses were administered in out-patient

SUBMITTER: Ravikumar D 

PROVIDER: S-EPMC8804007 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature